Compound Detail
CHEMBL4594406
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL4594406 |
| Name | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN |
| Phase | Approved |
| Structure Type | NONE |
| Therapeutic | ✓ Yes |
| Parent Compound | CHEMBL4594730 |
| Active Moiety | CHEMBL4594730 |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
9
Known Names
8
Indications
2
Mechanisms
Molecular Properties
1214.1
MW (Da)
Drug Information
| Molecule Type | Protein |
| First Approval | 2022 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Glutamate carboxypeptidase II binding agent | BINDING AGENT | Glutamate carboxypeptidase 2 | ✓ | ✓ |
| DNA disrupting agent | DISRUPTING AGENT | DNA | ✓ | ✓ |
Indications
Prostatic Neoplasms, Castration-Resistant Prostatic Neoplasms, Castration-Resistant Prostatic Neoplasms Prostatic Neoplasms Prostatic Neoplasms Carcinoma, Adenoid Cystic Urogenital Neoplasms Neoplasms
ATC Classification
V10XX05
lutetium (177Lu) vipivotide tetraxetan
Level 1: VARIOUS
Level 2: THERAPEUTIC RADIOPHARMACEUTICALS
Data from ChEMBL 36 via Core Engine